Abstract
The forkhead box O (FOXO) transcription factor FOXO1 functions as a tumor suppressor by regulating expression of genes involved in apoptosis, cell cycle arrest and oxidative detoxification. Here, we demonstrate that cyclin-dependent kinase 1 (CDK1) specifically phosphorylates FOXO1 at serine 249 (S249) in vitro and in vivo. Coimmunoprecipitation assays demonstrate that both endogenous CDK1 and ectopically expressed CDK1 form a protein complex with FOXO1 in prostate cancer (PCa) cells. In vitro protein binding assays reveal that CDK1 interacts directly with FOXO1. Accordingly, overexpression of CDK1 inhibits the transcriptional activity of FOXO1 in PCa cells through S249 phosphorylation on FOXO1. Consistent with the roles of FOXO3a and FOXO4 (two other members of the FOXO family) in cell cycle regulation, forced expression of FOXO1 causes a delay in the transition from G2 to M phase. This effect is blocked completely by overexpression of CDK1 and cyclin B1. Ectopic expression of constitutively active CDK1 also inhibits FOXO1-induced apoptosis in PCa cells. Moreover, we demonstrate that the inhibitory effect of FOXO1 on Ras oncogene-induced colony formation in fibroblasts is diminished by overexpression of CDK1. Given that CDK1 and cyclin B1 are often overexpressed in human cancers including PCa, our findings suggest that aberrant activation of CDK1 may contribute to tumorigenesis by promoting cell proliferation and survival via phosphorylation and inhibition of FOXO1.
Similar content being viewed by others
References
Aoki M, Jiang H, Vogt PK . (2004). Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci USA 101: 13613–13617.
Biggs III WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC . (1999). Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 96: 7421–7426.
Borkhardt A, Repp R, Haas OA, Leis T, Harbott J, Kreuder J et al. (1997). Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene 14: 195–202.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96: 857–868.
Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME . (2001). Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21: 952–965.
Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP . (2006). Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA 103: 15969–15974.
Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ . (2000). Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10: 1201–1204.
Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK et al. (2003). Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72: 270–280.
Fernandez-Zapico ME, Mladek A, Ellenrieder V, Folch-Puy E, Miller L, Urrutia R . (2003). An mSin3A interaction domain links the transcriptional activity of KLF11 with its role in growth regulation. EMBO J 22: 4748–4758.
Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K, Motoyama N . (2002). FOXO forkhead transcription factors induce G(2)–M checkpoint in response to oxidative stress. J Biol Chem 277: 26729–26732.
Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher III FJ, Emanuel BS et al. (1993). Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5: 230–235.
Gilley J, Coffer PJ, Ham J . (2003). FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162: 613–622.
Goga A, Yang D, Tward AD, Morgan DO, Bishop JM . (2007). Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 13: 820–827.
Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH et al. (1998). Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533–538.
Green DR, Evan GI . (2002). A matter of life and death. Cancer Cell 1: 19–30.
Greer EL, Brunet A . (2005). FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410–7425.
Hillion J, Le Coniat M, Jonveaux P, Berger R, Bernard OA . (1997). AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood 90: 3714–3719.
Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY et al. (2004). IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117: 225–237.
Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ . (2001). PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 276: 38830–38836.
Huang H, Muddiman DC, Tindall DJ . (2004a). Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem 279: 13866–13877.
Huang H, Regan KM, Lou Z, Chen J, Tindall DJ . (2006). CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314: 294–297.
Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM et al. (2005). Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 102: 1649–1654.
Huang H, Tindall DJ . (2007). Dynamic FoxO transcription factors. J Cell Sci 120: 2479–2487.
Huang H, Zegarra-Moro OL, Benson D, Tindall DJ . (2004b). Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene 23: 2161–2176.
Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman Jr RP, Muraca PJ et al. (1998). Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 16: 1302–1309.
Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman Jr RP, Ross JS . (1997). The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 80: 753–763.
Knockaert M, Greengard P, Meijer L . (2002). Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23: 417–425.
Kops GJ, De Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM . (1999). Direct control of the forkhead transcription factor AFX by protein kinase B. Nature 398: 630–634.
Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ et al. (2002). Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 22: 2025–2036.
Maddison LA, Huss WJ, Barrios RM, Greenberg NM . (2004). Differential expression of cell cycle regulatory molecules and evidence for a ‘cyclin switch’ during progression of prostate cancer. Prostate 58: 335–344.
Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ et al. (1996). Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 56: 4159–4163.
Matsuoka S, Ballif BA, Smogorzewska A, McDonald III ER, Hurov KE, Luo J et al. (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316: 1160–1166.
Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A . (2003). Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci USA 100: 11285–11290.
Medema RH, Kops GJ, Bos JL, Burgering BM . (2000). AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782–787.
Modur V, Nagarajan R, Evers BM, Milbrandt J . (2002). FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277: 47928–47937.
Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR . (2000). Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20: 8969–8982.
Ozen M, Ittmann M . (2005). Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res 11: 4701–4706.
Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z et al. (2007). FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128: 309–323.
Parker LL, Piwnica-Worms H . (1992). Inactivation of the p34cdc2–cyclin B complex by the human WEE1 tyrosine kinase. Science 257: 1955–1957.
Pinkston-Gosse J, Kenyon C . (2007). DAF-16/FOXO targets genes that regulate tumor growth in Caenorhabditis elegans. Nat Genet 39: 1403–1409.
Pinkston JM, Garigan D, Hansen M, Kenyon C . (2006). Mutations that increase the life span of C.elegans inhibit tumor growth. Science 313: 971–975.
Plas DR, Thompson CB . (2003). Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 278: 12361–12366.
Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR . (2002). A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2: 81–91.
Rena G, Guo S, Cichy SC, Unterman TG, Cohen P . (1999). Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 274: 17179–17183.
Rena G, Woods YL, Prescott AR, Peggie M, Unterman TG, Williams MR et al. (2002). Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO J 21: 2263–2271.
Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K et al. (2007). Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448: 811–815.
Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW et al. (2002). Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22: 7842–7852.
Seoane J, Le HV, Shen L, Anderson SA, Massague J . (2004). Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117: 211–223.
Sherr CJ, Roberts JM . (2004). Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699–2711.
Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK et al. (2000). Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60: 4000–4004.
Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM et al. (2002). The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 168: 5024–5031.
Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM et al. (2006). Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815–2825.
Tang ED, Nunez G, Barr FG, Guan KL . (1999). Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 274: 16741–16746.
Tran H, Brunet A, Grenier JM, Datta SR, Fornace Jr AJ, DiStefano PS et al. (2002). DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296: 530–534.
Woods YL, Rena G, Morrice N, Barthel A, Becker W, Guo S et al. (2001). The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. Biochem J 355: 597–607.
Wu X, Dong X, Liu W, Chen J . (2006). Characterization of CHEK2 mutations in prostate cancer. Hum Mutat 27: 742–747.
Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL . (1998). The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95: 15587–15591.
Acknowledgements
We thank DJ Tindall, KL Guan, H Piwnica-Worms, R Urrutia and F Farassati for plasmids and reagents, members of the Huang Lab for their stimulating discussion, V Shridhar and K Schwertfeger for their critical reading of the manuscript and Jacie Maguire for her assistance in the preparation of the manuscript. This work was supported in part by funds from the Department of Defense, USA (W81XWH-07-1-0137), and the Brainstorm Award from the University of Minnesota Cancer Center.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Liu, P., Kao, T. & Huang, H. CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene 27, 4733–4744 (2008). https://doi.org/10.1038/onc.2008.104
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.104
- Springer Nature Limited
Keywords
This article is cited by
-
Network and functional analyses of differentially expressed genes in gastric cancer provide new biomarkers associated with disease pathogenesis
Journal of the Egyptian National Cancer Institute (2023)
-
Targeting CDK1 in cancer: mechanisms and implications
npj Precision Oncology (2023)
-
The FOXO family of transcription factors: key molecular players in gastric cancer
Journal of Molecular Medicine (2022)
-
The biological function and clinical significance of STIL in osteosarcoma
Cancer Cell International (2021)
-
Adenosine A2A receptor signaling promotes FoxO associated autophagy in chondrocytes
Scientific Reports (2021)